Pharmaceutical

Chinese regulator grants priority review for InnoCare’s solid tumour treatment

China NMPA's Center for Drug Evaluation (CDE) has granted priority review for InnoCare Pharma's zurletrectinib (ICP-723)

May 6, 2025 - 06:00
Chinese regulator grants priority review for InnoCare’s solid tumour treatment
China NMPA's Center for Drug Evaluation (CDE) has granted priority review for InnoCare Pharma's zurletrectinib (ICP-723)
Read the original article

Tags:

Previous Article

TAE Life Sciences, Ohio State University partner to advance cancer drug development

Next Article

FDA accepts Novo Nordisk’s NDA submission for weight management therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Verastem files patent for combination treatment of FAK ...

Mar 24, 2024

Idorsia introduces Quviviq in Switzerland for chronic insomnia treatment

Idorsia introduces Quviviq in Switzerland for chronic i...

Jun 13, 2023

STAT+: Black men were likely underdiagnosed with lung problems because of bias in software, study suggests

STAT+: Black men were likely underdiagnosed with lung p...

Jun 4, 2023